Sarcoidosis is a systemic disease characterized by non-necrotic epithelioid granulomas that preferentially involve the respiratory tract [1]. In pulmonary sarcoidosis, granulomas develop throughout the lung parenchyma, notably in the perivascular and peribronchiolar interstitial spaces, as well as in the walls of small pulmonary arteries and veins [2]. This vascular involvement defines sarcoid vasculitis, which was classified among the vasculitides associated with systemic diseases at the 2012 Chapel Hill consensus conference [3]. Pulmonary hypertension (PH) is a major complication that occurs in 5% of patients with sarcoidosis and may cause death or require lung transplantation [4, 5, 6]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
No takes yet. Share an insight, caveat, or question.
Bernaudin et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: